{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Supermobilizers"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Normal Mobilizers"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Percentage of participants who were alive 1 year after transplant (OS)","groups":[{"description":"Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \\>= 8 x 10\\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\\< 2 x 10\\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.\n\nplerixafor: Given SC\n\nfilgrastim: Given SC\n\netoposide: Given IV\n\nleukapheresis: Undergo apheresis","id":"OG000","title":"Treatment (Stem Cell Supermobilization)"}],"paramType":"NUMBER","populationDescription":"All participants that had some mobilization","reportingStatus":"POSTED","timeFrame":"Up to 1 year post-transplant","title":"Overall Survival in Supermobilizers and Normal Mobilizers","type":"SECONDARY","unitOfMeasure":"percent of participants"}